SecBot SecBot
SECBOTREPLAY Home › Report › PCVX

PCVX · Vaxcyte dosed the first participant in a Phase 1 first-in-human study…

Vaxcyte, Inc. · PRESS-RELEASE filed Jun 2, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Jun 2, 2026 at 16:05 ET

Vaxcyte dosed the first participant in a Phase 1 first-in-human study of VAX-A1, a prophylactic vaccine candidate for Group A Streptococcus. This is an early-stage clinical milestone with no efficacy data yet; topline results are not expected until H2 2027.

  • First participant dosed in Phase 1 study of VAX-A1 for Group A Strep.
  • Study is randomized, double-blind, placebo-controlled, dose-escalation, two-stage, enrolling ~80 healthy adults aged 18-40.
  • Primary objective: safety and tolerability; secondary: antigen-specific immune responses.
  • Topline data expected in second half of 2027.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access